PRInnovation at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

PRInnovation takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on the PRImus-AD phase 2b study of the oral drug PRI-002, with its biomarker and safety data in early Alzheimer's disease.

Organization	CTAD 2026 Attendance
P PRInnovation Düsseldorf, Germany
Biotech Company set up by Germany's federal innovation agency SPRIND to sponsor the PRImus-AD phase 2 trial of Priavoid's oral drug PRI-002.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue PRImus-AD: Biomarker Profile Data of the phase 2b study treating early AD patients with the novel drug candidate PRI-002 (P018) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue PRImus-AD: Safety data of the Phase 2b study treating early AD patients with the novel drug candidate PRI-002 (P020) Anti-amyloid and anti-tau therapies

Organization

CTAD 2026 Attendance

PRInnovation

Düsseldorf, Germany

Biotech

Company set up by Germany's federal innovation agency SPRIND to sponsor the PRImus-AD phase 2 trial of Priavoid's oral drug PRI-002.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

PRImus-AD: Biomarker Profile Data of the phase 2b study treating early AD patients with the novel drug candidate PRI-002 (P018)

Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

PRImus-AD: Safety data of the Phase 2b study treating early AD patients with the novel drug candidate PRI-002 (P020)

Anti-amyloid and anti-tau therapies

Instantly find 20 buyers from PRInnovation

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction